| Literature DB >> 22963530 |
Juni Andréll1, Christopher G Tate.
Abstract
The number of structures of integral membrane proteins from higher eukaryotes is steadily increasing due to a number of innovative protein engineering and crystallization strategies devised over the last few years. However, it is sobering to reflect that these structures represent only a tiny proportion of the total number of membrane proteins encoded by a mammalian genome. In addition, the structures determined to date are of the most tractable membrane proteins, i.e., those that are expressed functionally and to high levels in yeast or in insect cells using the baculovirus expression system. However, some membrane proteins that are expressed inefficiently in these systems can be produced at sufficiently high levels in mammalian cells to allow structure determination. Mammalian expression systems are an under-used resource in structural biology and represent an effective way to produce fully functional membrane proteins for structural studies. This review will discuss examples of vertebrate membrane protein overexpression in mammalian cells using a variety of viral, constitutive or inducible expression systems.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22963530 PMCID: PMC3709882 DOI: 10.3109/09687688.2012.703703
Source DB: PubMed Journal: Mol Membr Biol ISSN: 0968-7688 Impact factor: 2.857
Structures of mammalian membrane proteins determined from protein overexpressed in mammalian cells.
| Membrane protein | Source | Cells used for protein production | Resolution of structure | Reference |
|---|---|---|---|---|
| Ammonia transporter RhCG | Human | HEK293S(TetR)-GnTI- | 2.1 Å | ( |
| Rhodopsin N2C/D282C/D113Q | Bovine | HEK293S(TetR)-GnTI- | 3.0 Å | ( |
| Rhodopsin N2C/D282C/M257Y | Bovine | HEK293S(TetR)-GnTI- | 3.3 Å | ( |
| Rhodopsin N2C/D282C | Bovine | COS-7 | 3.4 Å | ( |
| Connexin a1 (gap junction) | Human | BHK | 7.5 Å | ( |
*Structures were determined by X-ray diffraction except for the structure of connexin, which was determined by electron cryo-microscopy of 2-dimensional crystals that formed in BHK cells upon overexpression. There are numerous examples of low resolution structures determined by electron microscopy of membrane proteins isolated after expression in mammalian cells, but only examples of structures at better than 8 Å resolution are shown. Details of the expression systems and amounts of protein expressed are shown in Tables II and III.
Expression of membrane proteins using transient expression systems in mammalian cells.
| Membrane protein | Promoter | Cell line | Scale up | Expression levels | Amount purified | Reference |
|---|---|---|---|---|---|---|
|
| ||||||
| Neurokinin 1 receptor | SFV subgenomic | BHK-21 | – | 40 pmol/mg | – | ( |
| Histamine receptor H2 | SFV subgenomic | COS-7 | – | 80 pmol/mg | – | ( |
| α2β adrenergic receptor | SFV subgenomic | CHO | – | 175 pmol/mg mp; 8.8 million c/c | – | ( |
| Adenosine receptor A2A | SFV subgenomic | BHK-21 | – | 285 pmol/mg; 1–10 mg/l | – | ( |
| Glutamate transporter GLT1 | SFV subgenomic | BHK-21 | Stirrer flasks (8 l) 1 million cells/ml | 3.5 million c/c; 61 pmol/mg mp | 0.3 mg | ( |
| Bradykinin B2 receptor | SFV subgenomic | BHK-21 | – | 11 pmol/mg; 0.2 mg/l | – | ( |
| Aquaporin AQP3 | SFV subgenomic | various | 1 l glass roller bottles | ∼ 0.01 mg/l | – | ( |
| Aquaporin AQP6 | SFV subgenomic | various | – | <0.001 mg/l | – | ( |
| HCN2 channel | SFV subgenomic | various | – | ∼ 10 mg/l (+ misfolded) | – | ( |
| Purine receptor P2X2 | SFV subgenomic | various | – | ∼0.5 mg/l | – | ( |
| Purine receptor P2Y2 | SFV subgenomic | various | – | ∼ 10 mg/l | – | ( |
| Vasopressin receptor V2 | SFV subgenomic | various | – | ∼ 1 mg/l | – | ( |
| Angiotensin receptor AT1 | SFV subgenomic | BHK | – | 32 pmol/mg | – | ( |
| Muscarinic M3 receptor | SFV subgenomic | COS-7 | – | 27 pmol/mg | – | ( |
|
| ||||||
| TRH receptor | CMV | HeLa | – | 2 million c/c | – | ( |
|
| ||||||
| Neuropeptide Y receptor | Vaccinia 11K promoter | HeLa | – | 1 mg/l | – | ( |
|
| ||||||
| β2 adrenergic receptor | Adenovirus major late promoter | COS-1 | – | 18 pmol/mg | – | ( |
| Rhodopsin mutant | COS-7 | 50 × 15 cm plates | n.r. | ∼ 0.6 mg | ( | |
*Shown are some examples of membrane proteins expressed in mammalian cells at high-levels or where there are interesting comparisons between expression systems. Further examples can be found in (Grisshammer and Tate 1995, Sarramegna et al. 2003). Expression levels are shown in units as supplied in the primary publication: c/c, copies per cell; mg mp, milligram of membrane protein; n.r., not recorded.
Expression of membrane proteins in stable mammalian cell lines.
| Membrane protein | Promoter | Cell line | Scale up | Expression levels | Amount purified | Ref |
|---|---|---|---|---|---|---|
|
| ||||||
| β2 adrenergic receptor | CMV | CHO | – | 200 pmol/mg | 1.3 nmol (∼60 ug) | ( |
| Glucagon receptor | CMV | BHK | – | 78 pmol/mg | – | ( |
| Serotonin transporter | CMV | 293EBNA | – | 290,000 c/c | – | ( |
| Chemokine receptor D6 | CMV | L1.2 | 1 mg/5 × 109 cells | 2.5 million c/c | – | ( |
| Serotonin receptor 5HT2c | CMV | HEK293T | – | 140 pmol/mg; 3 million c/c | – | ( |
| Bradykinin receptor B2 | CMV | HEK293S | – | 3 million c/c; 60 pmol/mg mp | – | ( |
| Chemokine receptor CCR1 | CMV | Flp-In 293 | – | Relative fluorescence | – | ( |
|
| ||||||
| Serotonin transporter | Sindbis virus subgenomic | BHK-21 | Suspension culture: 0.5 million cells/ml | 240,000 c/c | – | ( |
| Serotonin transporter | β-globin | MEL | Suspension culture: 1 million cells/ml | 80,000 c/c | – | ( |
| Serotonin transporter | CMV/TetO2(pcDNA4) | T-REx 293 | – | 400,000 c/c | – | ( |
| Chemokine receptor CCR1 | CMV/TetO2(pcDNA4) | T-REx 293 | – | Relative fluorescence | ( | |
| Olfactory receptor 17-4 | CMV/TetO2(pcDNA4) | HEK293S-TetR | 50 × 15 cm plates | ∼ 30 ug/15 cm plate | 0.13 mg (50 plates) | ( |
| Olfactory receptor 17-4 | CMV/TetO2(pcDNA4) | HEK293S-GnTI- | Bioreactor (1.25 l): 9.6 million cells/ml | - | 3 mg per litre | ( |
| GABAA receptor α1β3 | CMV/TetO2(pcDNA4) | HEK293S-TetR | Bioreactor 3 l | 3.2 nmol/l; 14 pmol/mg | 1.4 mg | ( |
| Serotonin receptor 5HT3A | CMV/TetO2(pcDNA4) | HEK293S-TetR | Bioreactor 3 l | 9–34 nmol/l; 24–47 pmol/mg | 5.5 mg | ( |
| Serotonin transporter | CMV/TetO2(pcDNA4) | T-REx 293 | 3.9 × 108 cells from tissue culture plates | 1.22–1.67 million c/c | 0.59 nmol (∼50 ug) | ( |
| Vomeronasal receptor 1 | CMV/TetO2(pcDNA4) | HEK293S-GnTI- | Tissue culture plates (unknown quantity) | n.r | 1 mg/g of cells | ( |
| Chemokine receptor CCR1 | CMV/TetO2 | Flp-In T-REx 293 | – | Relative fluorescence only | – | ( |
| Rhodopsin | CMV/TetO2(pACMV) | HEK293S-TetR | Bioreactor (5.5 l): 5 million cells/ml | 9 mg/l | – | (Reeves et al. 2002b) |
| Rhodopsin | CMV/TetO2(pACMV) | HEK293S-GnTI- | Bioreactor (1.1 l): 4 million cells/ml | 6 mg/l | – | (Reeves et al. 2002a) |
| β2 adrenergic receptor | CMV/TetO2(pACMV) | HEK293S-TetR | Tissue culture plates | 220 pmol/mg mp | 12 ug/15 cm plate | ( |
| Bradykinin receptor B2 | CMV/TetO2(pACMV) | HEK293S-TetR | – | 100 pmol/mg mp; 5.5 million c/c | ( | |
| Chemokine receptor CCR1 | CMV/TetO2(pACMV) | HEK293S-TetR | CellStack or spinner flasks | n.r. | 0.1–0.2 mg/ 109 cells | ( |
| Tetraspanin CD81 | CMV/TetO2(pACMV) | HEK293S-TetR | 15 cm tissue culture plates | ∼ 26 ug/30 million cells | – | ( |
| Glucagon receptor | CMV/TetO2(pACMV) | HEK293S-GnTI- | 10 cm plates | 1.2 ug/mg mp | – | ( |
| Rhodopsin mutants | CMV/TetO2(pACMV) | HEK293S-GnTI- | Wave bioreactor 10 l | n.r | ∼0.5 mg per litre | ( |
| Ammonia transporter RhCG | CMV/TetO2(pACMV) | HEK293S-GnTI- | Wave bioreactor: 1 million cells/ml | n.r. | 0.5 mg per litre | ( |
*Shown are some examples of membrane proteins expressed in mammalian cells at high-levels or where there are interesting comparisons between expression systems. Further examples can be found in (Grisshammer and Tate 1995, Sarramegna et al. 2003). Expression levels are shown in units as supplied in the primary publication: c/c, copies per cell; mg mp, milligram of membrane protein; n.r., not reported.
**Personal communication.